{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biologic+therapy+versus+no+biologic+therapy", "query": { "intervention": "Biologic therapy versus no biologic therapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 56, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biologic+therapy+versus+no+biologic+therapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T21:07:18.526Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04280471", "title": "Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Graft Versus Host Disease", "Gastrointestinal Tract Acute Graft Versus Host Disease", "Severe Gastrointestinal Tract Acute Graft Versus Host Disease", "Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease" ], "interventions": [ { "name": "Fecal Microbiota Transplantation Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2023-09-01", "completion_date": "2025-12-01", "has_results": false, "last_update_posted_date": "2023-09-22", "last_synced_at": "2026-09-27T21:07:18.526Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04280471" }, { "nct_id": "NCT02356159", "title": "Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Hodgkin's Lymphoma", "Non-Hodgkin's Lymphoma", "Acute Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Conditioning chemotherapy", "type": "DRUG" }, { "name": "TMS", "type": "DRUG" }, { "name": "FLAG", "type": "DRUG" }, { "name": "EPOCH-F", "type": "DRUG" }, { "name": "Hematopoietic stem cell transplant", "type": "PROCEDURE" }, { "name": "Palifermin", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Epinephrine", "type": "DRUG" }, { "name": "IV Saline", "type": "OTHER" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "MUGA", "type": "DIAGNOSTIC_TEST" }, { "name": "DEXA", "type": "DIAGNOSTIC_TEST" }, { "name": "CT chest", "type": "DIAGNOSTIC_TEST" }, { "name": "PET", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "BM aspirate", "type": "PROCEDURE" }, { "name": "BM biopsy", "type": "PROCEDURE" }, { "name": "Lumbar puncture", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2015-09-24", "completion_date": "2025-03-25", "has_results": true, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-09-27T21:07:18.526Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02356159" }, { "nct_id": "NCT02753595", "title": "Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Eribulin mesylate", "type": "DRUG" }, { "name": "Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)", "type": "OTHER" }, { "name": "Biologic: PEGylated recombinant human hyaluronidase", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2016-07-13", "completion_date": "2019-08-16", "has_results": true, "last_update_posted_date": "2020-07-13", "last_synced_at": "2026-09-27T21:07:18.526Z", "location_count": 7, "location_summary": "Whittier, California • Atlanta, Georgia • Newnan, Georgia + 4 more", "locations": [ { "city": "Whittier", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Newnan", "state": "Georgia" }, { "city": "Anderson", "state": "Indiana" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02753595" }, { "nct_id": "NCT07209371", "title": "Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "IgA Monoclonal Gammopathy of Undetermined Significance", "Non-IgM Monoclonal Gammopathy of Undetermined Significance" ], "interventions": [ { "name": "Rifaximin", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2026-01-22", "completion_date": "2028-05-01", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-09-27T21:07:18.526Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07209371" }, { "nct_id": "NCT06735170", "title": "Tuberoplasty Versus Balloon Spacer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Rotator Cuff Tears" ], "interventions": [ { "name": "biologic tuberoplasty", "type": "PROCEDURE" }, { "name": "subacromial balloon spacer", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 40, "start_date": "2024-12-02", "completion_date": "2026-11-26", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-09-27T21:07:18.526Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06735170" }, { "nct_id": "NCT04229979", "title": "Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Galinpepimut-S", "type": "BIOLOGICAL" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Observation", "type": "OTHER" }, { "name": "GM-CSF", "type": "BIOLOGICAL" }, { "name": "Montanide", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Sellas Life Sciences Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2021-02-08", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-09-27T21:07:18.526Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Los Angeles, California • Whittier, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04229979" }, { "nct_id": "NCT01116232", "title": "Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "management of therapy complications", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 4, "start_date": "2010-08", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2019-03-26", "last_synced_at": "2026-09-27T21:07:18.526Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01116232" }, { "nct_id": "NCT02785952", "title": "Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Squamous Cell Lung Carcinoma", "Stage IV Squamous Cell Lung Carcinoma AJCC v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2015-12-29", "completion_date": "2027-04-01", "has_results": true, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-09-27T21:07:18.526Z", "location_count": 1201, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 735 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02785952" }, { "nct_id": "NCT01175785", "title": "Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Previously Treated Myelodysplastic Syndromes", "Refractory Anemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Excess Blasts in Transformation", "Relapsing Chronic Myelogenous Leukemia", "Secondary Myelodysplastic Syndromes" ], "interventions": [ { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "ex vivo-expanded cord blood progenitor cell infusion", "type": "BIOLOGICAL" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION", "OTHER" ], "sponsor": "Nohla Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "45 Years", "sex": "ALL", "summary": "6 Months to 45 Years" }, "enrollment_count": 15, "start_date": "2010-08", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-09-27T21:07:18.526Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01175785" }, { "nct_id": "NCT05436418", "title": "The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Peripheral Blood Stem Cell Transplantation", "Hematopoietic Stem Cell Transplantation" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Total Body Irradiation (TBI)", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mycophenolate Mofeti", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Allogeneic HSCT", "type": "PROCEDURE" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": 260, "start_date": "2022-11-18", "completion_date": "2028-06-25", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-09-27T21:07:18.526Z", "location_count": 2, "location_summary": "Duarte, California • Bethesda, Maryland", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05436418" } ] }